

**DATASET**

	A	B	C	D
1	<b>NCT Number</b>	<b>Title</b>	<b>Recruitment</b>	<b>Study Results</b>
2	NCT02539407	Population Pharmacokinetics of Anti-infectives in Critically Ill Children	Recruiting	No Results Available
3	NCT02935374	Effect of Antimicrobial Treatment of Acute Otitis Media on the Intestinal Microbiome in Children	Not yet recruiting	No Results Available
4	NCT02899143	Short-course Antimicrobial Therapy in Sepsis	Recruiting	No Results Available
5	NCT01595529	The SCOUT Study: Short Course Therapy for Urinary Tract Infections in Children	Recruiting	No Results Available
6	NCT02380352	Short-course Antimicrobial Therapy for Paediatric Respiratory Infections	Not yet recruiting	No Results Available
7	NCT02891915	Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children	Recruiting	No Results Available
8	NCT02746276	Optimising Antibiotic Treatment for Sick Malnourished Children	Recruiting	No Results Available
9	NCT02917551	BALANCE on the Wards: A Pilot RCT	Not yet recruiting	No Results Available
10	NCT01243437	A Clinical Trial to Evaluate the Safety and Efficacy of Ciprofloxacin in the Treatment of Plague in Children	Recruiting	No Results Available
11	NCT02635191	Tailored Therapy for Helicobacter Pylori in Children	Recruiting	No Results Available
12	NCT01522105	Daptomycin in Pediatric Patients With Bacterial Meningitis	Recruiting	No Results Available
13	NCT02456974	Antibiotic Dosing in Pediatric Intensive Care	Recruiting	No Results Available
14	NCT00579956	A Randomized Double Blinded Comparison of Ceftazidime and Meropenem in Severe Melioidosis	Recruiting	No Results Available
15	NCT00545961	Middle Meatal Bacteriology During Acute Respiratory Infection in Children	Not yet recruiting	No Results Available
16	NCT01431326	Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care	Recruiting	No Results Available
17	NCT02475876	PK of Clindamycin and Trimethoprim-sulfamethoxazole in Infants and Children	Recruiting	No Results Available
18	NCT01420341	Co-trimoxazole as Maintenance Therapy for Melioidosis	Recruiting	No Results Available
19	NCT02266706	Pharmacokinetic and Safety Study of Ceftolozane/Tazobactam in Pediatric Participants Receiving	Recruiting	No Results Available
20	NCT00867789	Antibiotics Versus Placebo in the Treatment of Abscesses in the Emergency Department	Recruiting	No Results Available
21	NCT02879981	A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis	Not yet recruiting	No Results Available
22	NCT01269541	MESS-study MRSA Eradication Study Sk'ne	Recruiting	No Results Available
23	NCT02276482	Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cS	Recruiting	No Results Available
24	NCT02663596	Safety and TDM of Continuous Infusion Vancomycin Through Continuous Renal Replacement Th	Not yet recruiting	No Results Available
25	NCT02555059	Special Drug Use Investigation of Ciproxan Injection in Pediatrics	Recruiting	No Results Available
26	NCT02297815	Comparative Effectiveness of Antibiotics for Respiratory Infections	Recruiting	No Results Available
27	NCT02224040	Typhoid Fever: Combined vs. Single Antibiotic Therapy	Recruiting	No Results Available
28	NCT02775968	Population Pharmacokinetics of Cephalosporins and Macrolides in Chinese Children With Comm	Not yet recruiting	No Results Available
29	NCT02687906	Dose-finding, Pharmacokinetics, Safety, and Tolerability of Meropenem-Vaborbactam in Pediatr	Recruiting	No Results Available
30	NCT02783859	Hospitalised Pneumonia With Extended Treatment (HOPE) Study	Recruiting	No Results Available
31	NCT01994993	Antibiotic Safety (SCAMP)	Recruiting	No Results Available

	A	B	C	D
32	NCT02258763	Trial on the Ideal Duration of Oral Antibiotics in Children With Pneumonia	Recruiting	No Results Available
33	NCT02688790	Study Evaluate the PK Profile of Dalbavancin in Hospitalized Infants and Neonates Patients With	Recruiting	No Results Available
34	NCT00323219	Oral Moxifloxacin Versus Cefazolin and Oral Probenecid in the Management of Skin and Soft Tis	Recruiting	No Results Available
35	NCT02750761	A Study of Oral and Intravenous (IV) Tedizolid Phosphate in Hospitalized Participants, Ages 2 to	Recruiting	No Results Available
36	NCT02466438	Safety and Pharmacokinetics of Piperacillin-tazobactam Extended Infusion in Infants and Childre	Recruiting	No Results Available
37	NCT02260102	Temocillin Pharmacokinetics in Paediatrics	Not yet recruiting	No Results Available
38	NCT02694458	Comparison of Two Dosage Adjustment Strategies of Vancomycin in Children	Recruiting	No Results Available
39	NCT01540838	Slow Initial beta-lactam Infusion With High-dose Paracetamol to Improve the Outcomes of Child	Recruiting	No Results Available
40	NCT00368498	A Trial to Evaluate the Loading Dose Required to Achieve Therapeutic Serum Teicoplanin Concer	Recruiting	No Results Available
41	NCT01785641	Single Versus Combined Antibiotic Therapy for Bacterial Peritonitis in CAPD Patients	Recruiting	No Results Available
42	NCT02554383	Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit?	Recruiting	No Results Available
43	NCT01265173	Comparison of Efficacy of Cefotaxime, Ceftriaxone, and Ciprofloxacin for the Treatment of Spon	Recruiting	No Results Available
44	NCT02335905	Ceftaroline for Treatment of Hematogenously Acquired Staphylococcus Aureus Osteomyelitis in	Recruiting	No Results Available
45	NCT02922686	Penicillin for the Emergency Department Outpatient Treatment of CELLulitis	Not yet recruiting	No Results Available
46	NCT02848820	Initial Non-operative Treatment Strategy Versus Appendectomy Treatment Strategy for Simple A	Not yet recruiting	No Results Available
47	NCT02475733	Evaluation of Safety, Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Childern A	Recruiting	No Results Available
48	NCT02372461	Randomized Trial of Amoxicillin Versus Placebo for (Fast Breathing) Pneumonia	Recruiting	No Results Available
49	NCT01553006	Study of Cefditoren Pivoxil in Treatment of Childhood With Acute Rhinosinusitis	Recruiting	No Results Available
50	NCT02527681	Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated W	Recruiting	No Results Available
51	NCT02210169	RCT of Continuous Versus Intermittent Infusion of Vancomycin in Neonates	Recruiting	No Results Available
52	NCT02497781	Evaluation of Safety, Pharmacokinetics and Efficacy of Ceftazidime and Avibactam (CAZ-AVI ) Co	Recruiting	No Results Available
53	NCT02814916	Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children,	Not yet recruiting	No Results Available
54	NCT02210325	Efficacy and Safety Study of Oral Solithromycin Compared to Intramuscular Ceftriaxone Plus Ora	Recruiting	No Results Available
55	NCT02801370	Phase 3 Study of OTO-201 in Acute Otitis Externa	Recruiting	No Results Available
56	NCT02760420	3 Days Amoxicillin Versus Placebo for Fast Breathing Childhood Pneumonia in Malawi	Recruiting	No Results Available
57	NCT02678195	3 Days Versus 5 Days Amoxicillin for Chest-indrawing Childhood Pneumonia in Malawi	Recruiting	No Results Available
58	NCT02605122	Safety and Efficacy of Solithromycin in Adolescents and Children With Community-acquired Bact	Recruiting	No Results Available
59	NCT02570490	Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin	Recruiting	No Results Available
60	NCT02443285	Is Spontaneous Bacterial Peritonitis Still Responding to 3rd Generation Cephalosporins?	Recruiting	No Results Available
61	NCT02334124	Comparing the Intravenous Treatment of Skin Infections in Children, Home Versus Hospital	Recruiting	No Results Available
62	NCT02218372	A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Va	Recruiting	No Results Available

	A	B	C	D
63	NCT01032499	Open and Comparative Study to Measure Tolerability and Efficacy of Taro Elixir	Not yet recruiting	No Results Available
64	NCT02598362	Pharmacokinetics of Ciprofloxacin in Pediatric Patients	Recruiting	No Results Available
65	NCT02878031	Community Case Management of Chest Indrawing Pneumonia	Recruiting	No Results Available
66	NCT02790996	Neonatal Vancomycin Trial	Not yet recruiting	No Results Available
67	NCT02712307	Study of 5 and 10 Days Treatment With Penicillin Against Sore Throat Caused by Streptococci	Recruiting	No Results Available
68	NCT02424734	Safety, Tolerability and Efficacy of Ceftaroline in Paediatrics With Late-Onset Sepsis	Recruiting	No Results Available
69	NCT02134301	Open-Label, Dose-Finding, Pharmacokinetics, Safety and Tolerability Study of Oritavancin in Ped	Recruiting	No Results Available
70	NCT02013141	An Open-Label Study of the Pharmacokinetics of a Single Dose of Telavancin in Pediatric Subject	Recruiting	No Results Available
71	NCT01427842	Dose Enhancement of Vancomycin IN Everyday Patients	Recruiting	No Results Available
72	NCT01278017	The Role of Short-course Ceftriaxone Therapy in the Treatment of Severe Nontyphoidal Salmonel	Recruiting	No Results Available
73	NCT00988026	Safety and Efficacy Comparison of Minocycline Microgranules Versus Lymecycline in the Treatm	Recruiting	No Results Available
74	NCT02288234	Telavancin Observational Use Registry (TOUR)	Recruiting	No Results Available
75	NCT01304459	Vancomycin Serum Concentrations in Pediatric Oncology Patients Under Intensive Care	Recruiting	No Results Available
76	NCT01173575	Assessment of the Efficacy of FOSFOMYCIN in Patients With Bacterial Infection	Recruiting	No Results Available
77	NCT01778634	Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm	Recruiting	No Results Available

	E	F
1	<b>Indication</b>	<b>Infection category</b>
2	Proven or suspected infection (in patients on PICU)	9
3	Acute Otitis Media	3
4	Sepsis	8
5	Urinary Tract Infections (UTI)	7
6	Community-acquired Pneumonia (CAP)	4
7	Pneumonia	4
8	Proven or suspected infection in patients with malnutrition	9
9	Bacteremia	8
10	Plague	8
11	Helicobacter Pylori Infection	7
12	Meningitis	1
13	Proven or suspected bacterial infection (Pharmacokinetics)	9
14	Melioidosis	8
15	Acute Respiratory Infection   Sinusitis	3
16	Various infections (including nosocomial Pneumonia, CAP, Acute Bac	Various
17	Bacterial Infections	9
18	Melioidosis	8
19	Proven or Suspected Gram-negative Bacterial Infection	9
20	Abscess	1
21	Bronchitis	4
22	Throatcarriers of MRSA	3
23	Acute Skin and Soft Tissue infections (aSSTIs)	2
24	Proven or suspected bacterial infection (in CRRT patients)	9
25	Cystitis / Pyelonephritis	7
26	Acute Upper Respiratory Tract Infections (ARTIs)	3
27	Typhoid Fever	8
28	Community Acquired Pneumonia (CAP)	4
29	Bacterial Infections	9
30	Pneumonia	4
31	Complicated Intra Abdominal Infections (cIAIs)	6

	E	F
32	Pneumonia	4
33	Bacterial Infections	9
34	Cellulitis	2
35	Gram-Positive Bacterial Infections	9
36	Infection	9
37	Urinary Tract Infection or suspected Cholangitis	7
38	Methicillin-resistant Staphylococcal Infections	9
39	Bacterial Meningitis	1
40	Staphylococcal Infections	9
41	Peritonitis (in CAPD patients)	6
42	Acute Sinusitis (Respiratory Tract Infections)	3
43	SBP in patients with Liver Cirrhosis	6
44	Hematogenously Acquired Staphylococcus Aureus Osteomyelitis	5
45	Cellulitis or Wound Infection	8
46	Appendicitis	6
47	Complicated Intra-abdominal Infections (cIAls)	6
48	Pneumonia (fast-breathing)	4
49	Rhinosinusitis	3
50	Bacterial Infections	9
51	Sepsis	8
52	Complicated Urinary Tract Infections (cUTIs)	7
53	Methicillin-Resistant Staphylococcus Aureus Skin Infection	2
54	Uncomplicated Urogenital Gonorrhea	7
55	Acute Otitis Externa	3
56	Pneumonia	4
57	Pneumonia	4
58	Community-acquired Bacterial Pneumonia	4
59	Acute Bacterial Skin and Skin Structure Infections	2
60	Primary Bacterial Peritonitis	6
61	Cellulitis	8
62	Clostridium Difficile-associated Diarrhea (CDAD)	6

	E	F
63	Acne Vulgaris II or III Degree	2
64	Urinary Tract Infection or Pyelonephritis	7
65	Pneumonia	4
66	Late Onset Neonatal Sepsis	8
67	Tonsillitis	3
68	Late-onset Sepsis	8
69	Gram Positive Bacterial Infections	9
70	Gram-Positive Bacterial Infections	9
71	Vancomycin Therapy	9
72	Diarrhea	6
73	Mild to Moderate Acne	2
74	Hospital Acquired Bacterial Pneumonia (HAP), Complicated Skin and	Various
75	Infection	9
76	Bacterial Infection	9
77	Eradicate ureaplasma respiratory tract infection from preterm infant	4

	G	H	I	J
1	<b>Interventions</b>	<b>Antibiotic class (J01 code)</b>	<b>Gender</b>	<b>Age</b>
2	Antiinfectives (beta-lactam, aminoglycoside, glycopeptide, fluoroquinolone,	Various	Both	Up to 18 Years
3	Amoxicillin, Amoxicillin-Potassium Clavulanate, Macrolide	Various	Both	6 Months to 7 Years
4	Antibiotic	J01	Both	Up to 18 years
5	Trimethoprim sulfamethoxazole, cefixime, or cephalexin	Various	Both	2 Months to 10 Years
6	Amoxicillin	J01C	Both	6 Months to 10 Years
7	Amoxicillin, Amoxicillin-clavulanate, Cefdinir	Various	Both	6 Months to 71 Months
8	Ceftriaxone, Metronidazole	J01D	Both	2 Months to 59 Months
9	7 days vs 14 days of adequate antibiotic treatment	J01	Both	Up to 18 years
10	Ciprofloxacin, doxyxcycline	Various	Both	8 Years and older
11	Tailored vs standard therapy (Amoxicillin, Clarithromycin, Metronidazole, Ra	Various	Both	4 Years to 18 Years
12	Daptomycin	J01X	Both	3 Months to 16 Years
13	Amoxicillin-clavulanate, Piperacilline-tazobactam, Vancomycin	Various	Both	Up to 16 Years
14	Meropenem, Ceftazidime	J01D	Both	15 Years and older
15	Amoxicillin clavulanate acid	J01C	Both	6 Years to 13 Years
16	Various drugs (Ceftazidime, Ciprofloxacin, Clindamycin, Doxycycline, Levoflo	Various	Both	Up to 18 years
17	Clindamycin, Trimethoprim-sulfamethoxazole	Various	Both	1 Month to 16 Years
18	Co-trimoxazole	J01E	Both	15 Years and older
19	Ceftolozane/Tazobactam	J01D	Both	Up to 17 Years
20	Trimethoprim-sulfamethoxazole	J01E	Both	3 Months to 17 Years
21	Guaifenesin, Sulfamethoxazole trimethoprim	J01E	Both	4 Years to 14 Years
22	Systemic Rifampin and Clindamycine/Trimehoprimsulfa, or Topical mupiroci	Various	Both	5 Years and older
23	Tedizolid Phosphate	J01X	Both	12 Years to 18 Years
24	Vancomycin	J01X	Both	Up to 18 years
25	Ciprofloxacin	J01F	Both	Up to 14 Years
26	Antibiotics (Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefurox	Various	Both	6 Months to 18 Years
27	Ceftriaxone, Ceftriaxone/azithromycin, Azithromycin, Azithromycin/cefixime	Various	Both	2 Years to 80 Years
28	Cephalosporins and Macrolides	Various	Both	1 Year to 18 Years
29	Carbavance	J01D	Both	Up to 17 Years
30	Amoxicillin-clavulanic Acid	J01C	Both	3 Months to 5 Years
31	Ampicillin/metronidazole/gentamicin/clindamycin/Piperacillin-tazobactam c	Various	Both	Up to 120 Days

	G	H	I	J
32	Amoxicillin-Potassium Clavulanate	J01C	Both	3 Months to 59 Months
33	Dalbavancin	J01X	Both	Up to 28 Days
34	Cefazolin/Moxifloxacin	Various	Both	Up to 18 Years
35	Tedizolid Phosphate	J01X	Both	2 Years to 11 Years
36	Piperacillin-tazobactam	J01C	Both	2 Months to 6 Years
37	Temocillin	J01C	Both	6 Months to 3 Years
38	Vancomycin	J01X	Both	1 Month to 16 Years
39	Beta-lactam	J01C	Both	2 Months to 15 Years
40	Teicoplanin	J01X	Both	16 Years and older
41	Ceftazidime/ciprofloxacin, Ceftazidime, Cefazolin/gentamicin, Cefazolin	Various	Both	15 Years and older
42	Amoxicillin-clavulanate	J01C	Both	2 Years to 11 Years
43	Cefotaxime, Ceftriaxone, Ciprofloxacin	Various	Both	16 Years and older
44	Ceftaroline Fosamil	J01D	Both	1 Year to 17 Years
45	Flucloxacillin, Phenoxyethylpenicillin	J01C	Both	16 Years and older
46	Augmentin/Gentamicin, Appendectomy	J01C	Both	7 Years to 17 Years
47	Ceftazidime-avibactam, Meropenem, Metronidazole	Various	Both	3 Months to 18 Years
48	Amoxicillin	J01C	Both	2 Months to 59 Months
49	Cefditoren pivoxil	J01D	Both	1 Year to 15 Years
50	Ceftobiprole	J01D	Both	Up to 3 Months
51	Vancomycin	J01X	Both	Up to 90 Days
52	Ceftazidime-avibactam, Cefepime	J01D	Both	3 Months to 18 Years
53	Dalbavancin single dose	J01X	Both	3 Months to 17 Years
54	Solithromycin, Ceftriaxone, Azithromycin	Various	Both	15 Years and older
55	Ciprofloxacin	J01M	Both	6 Months and older
56	Amoxicillin	J01C	Both	2 Months to 59 Months
57	Amoxicillin	J01C	Both	2 Months to 59 Months
58	Solithromycin	J01F	Both	2 Months to 17 Years
59	Sodium fusidate, Linezolid	J01X	Both	12 Years and older
60	Cefotaxime, Ceftriaxone	J01D	Both	Up to 18 Years
61	Ceftriaxone, Flucloxacillin	Various	Both	6 Months to 18 Years
62	Fidaxomicin, Vancomycin	J01X	Both	Up to 17 Years



	G	H	I	J
63	Taro Elixir	J01A	Both	14 Years and older
64	Ciprofloxacin	J01M	Both	3 Months to 17 Years
65	Amoxicillin	J01C	Both	2 Months to 59 Months
66	Vancomycin	J01X	Both	Up to 90 Days
67	Phenoxymethylpenicillin	J01C	Both	6 Years and older
68	Ceftaroline Fosamil	J01D	Both	Up to 59 Days
69	Oritavancin	J01X	Both	Up to 18 Years
70	Telavancin	J01X	Both	1 Year to 17 Years
71	Vancomycin	J01X	Both	16 Years and older
72	Ceftriaxone	J01D	Both	3 Months to 18 Years
73	Minocycline, Lymecycline	J01A	Both	14 Years to 30 Years
74	Telavancin	J01X	Both	Up to 18 Years
75	Vancomycin	J01X	Both	Up to 18 Years
76	Fosfomycin	J01X	Both	Up to 18 Years
77	Azithromycin	J01F	Both	0 to 72 hours

	K	L	M	N	O
1	Age group	Estimated enrollment	Location	Income class	Geographic region
2	8	1850	France	High income	Europe
3	9	150	Finland	High income	Europe
4	8	320	Italy	High income	Europe
5	9	746	United States	High income	North America
6	9	270	Canada	High income	North America
7	9	400	United States	High income	North America
8	9	80	Kenya	Lower middle income	Africa
9	8	50	Canada	High income	North America
10	11	200	Uganda	Low income	Africa
11	11	200	China	Upper middle income	Asia
12	10	5	Switzerland	High income	Europe
13	8	200	Belgium	High income	Europe
14	5	750	Thailand	Upper middle income	Asia
15	11	120	Finland	High income	Europe
16	8	3000	Various (United States, Canada)	High income	International
17	10	54	United States	High income	North America
18	5	800	Thailand	Upper middle income	Asia
19	8	36	United States	High income	North America
20	10	200	United States	High income	North America
21	11	50	Peru	Upper middle income	Latin America
22	11	69	Sweden	High income	North America
23	5	162	Various (United States, Argentina)	Upper middle to High income	International
24	8	10	United States	High income	North America
25	8	45	Japan	High income	Asia
26	10	117000	United States	High income	North America
27	11	120	Nepal	Low income	Asia
28	10	750	China	Upper middle income	Asia
29	8	56	United States	High income	North America
30	9	314	Various (Australia, Malaysia)	High income	Oceania
31	6	284	Various (United States, Canada)	High income	North America

	K	L	M	N	O
32	9	300	Malaysia	Upper middle income	Asia
33	2	24	United States	High income	North America
34	8	390	Canada	High income	North America
35	4	32	United States	High income	North America
36	9	141	Canada	High income	North America
37	9	45	Belgium	High income	Europe
38	10	100	France	High income	Europe
39	10	400	Angola	Upper middle income	Africa
40	5	20	Taiwan, China	High income	Asia
41	5	300	Thailand	Upper middle income	Asia
42	4	688	United States	High income	North America
43	5	261	Republic of Korea	High income	Asia
44	10	18	United States	High income	North America
45	5	414	Ireland	High income	Europe
46	11	334	Netherlands	High income	Europe
47	10	102	Various (United States, Argent	Upper middle to High income	International
48	9	2500	Pakistan	Lower middle income	Asia
49	10	120	Thailand	Upper middle income	Asia
50	6	45	Various (Belgium, Germany, Li	High income	Europe
51	6	200	Australia	High income	Oceania
52	10	102	Various (United States, Czech	Upper middle to High income	International
53	10	300	United States	High income	North America
54	5	300	Various (United States, Austra	High income	International
55	10	500	Various (United States, Canad	High income	North America
56	9	2000	Malawi	Low income	Africa
57	9	2000	Malawi	Low income	Africa
58	10	400	Various (United States, Bulgar	High income	International
59	5	712	Various (United States, Puertc	High income	International
60	8	100	Egypt	Lower middle income	Africa
61	10	188	Australia	High income	Oceania
62	8	144	Various (United States, Belgiu	High income	International

	K	L	M	N	O
63	5	120	Brazil	Upper middle income	Latin America
64	10	20	Belgium	High income	Europe
65	9	308	Nigeria	Lower middle income	Africa
66	6	300	Various (United Kingdom, France)	High income	Europe
67	11	432	Sweden	High income	Europe
68	7	24	Various (United States, Hungary)	High income	International
69	8	60	United States	High income	North America
70	10	32	United States	High income	North America
71	5	100	Australia	High income	Oceania
72	10	200	Taiwan, China	High income	Asia
73	5	168	Mexico	High income	North America
74	8	1000	United States	High income	North America
75	8	50	Brazil	Upper middle income	Latin America
76	8	200	Various (Austria, Germany)	High income	Europe
77	1	180	United States	High income	North America

	P	Q	R	S	T
1	<b>Collaborators</b>	<b>Sponsor</b>	<b>Study Types</b>	<b>Phase</b>	<b>Endpoint classification</b>
2	Assistance Publique - Hopitaux de Paris	Hospital	Observational	Not applicable	Pharmacokinetics
3	University of Oulu Oulu University Hospital	University	Interventional	Phase 4	Efficacy
4	Ospedale Santa Maria delle Croci	Hospital	Interventional	Phase 2	Safety/Efficacy
5	Children's Hospital of Philadelphia Children's Ho	Hospital	Interventional	Phase 2	Safety/Efficacy
6	Hamilton Health Sciences Corporation Children's	Hospital	Interventional	Phase 4	Safety/Efficacy
7	National Institute of Allergy and Infectious Disease	NIH	Interventional	Phase 4	Efficacy
8	University of Oxford KEMRI Wellcome Trust Rese	University	Interventional	Phase 2	Pharmacokinetics
9	Sunnybrook Health Sciences Centre	Hospital	Interventional	Not specified	Efficacy
10	Centers for Disease Control and Prevention MRC	CDC	Interventional	Phase 2	Safety/Efficacy
11	Beijing Children's Hospital	Hospital	Interventional	Phase 4	Safety/Efficacy
12	University Hospital Inselspital, Berne	Hospital	Interventional	Phase 1	Pharmacokinetics
13	University Hospital, Ghent University Hospital, A	Hospital	Observational	Not applicable	Pharmacokinetics
14	University of Oxford Mahidol University Wellcor	University	Interventional	Not specified	Efficacy
15	Oulu University Hospital	University	Interventional	Phase 4	Safety/Efficacy
16	Daniel Benjamin Eunice Kennedy Shriver Nationa	University	Observational	Not applicable	Pharmacokinetics
17	Michael Cohen-Wolkowicz Eunice Kennedy Shriv	University	Interventional	Phase 1	Pharmacokinetics
18	Khon Kaen University	University	Interventional	Not specified	Efficacy
19	Cubist Pharmaceuticals LLC	Industry	Interventional	Phase 1	Pharmacokinetics
20	Children's Mercy Hospital Kansas City Blue Cross	Hospital	Interventional	Not specified	Efficacy
21	Hoffmann-La Roche	Industry	Observational	Not applicable	Safety
22	Region Skane	Hospital	Interventional	Not specified	Efficacy
23	Cubist Pharmaceuticals LLC	Industry	Interventional	Phase 3	Safety
24	Drexel University The Center for Pediatric Pharm	University	Interventional	Phase 1	Safety
25	Bayer	Industry	Observational	Not applicable	Safety/Efficacy
26	Children's Hospital of Philadelphia	Hospital	Observational	Not applicable	Safety/Efficacy
27	Sheba Medical Center	Hospital	Interventional	Phase 4	Efficacy
28	Beijing Children's Hospital	Hospital	Observational	Not applicable	Pharmacokinetics
29	Rempex Pharmaceuticals (a wholly owned subsidi	Industry	Interventional	Phase 1	Safety
30	Menzies School of Health Research Griffith Univ	University	Interventional	Phase 4	Safety/Efficacy
31	Michael Cohen-Wolkowicz The EMMES Corpora	University	Interventional	Phase 2-3	Safety

	P	Q	R	S	T
32	University of Malaya   Menzies School of Health Research	University	Interventional	Phase 4	Efficacy
33	Durata Therapeutics Inc., an affiliate of Allergan	Industry	Interventional	Phase 1	Pharmacokinetics
34	University of British Columbia	University	Interventional	Phase 3	Efficacy
35	Merck Sharp & Dohme Corp.	Industry	Interventional	Phase 1	Pharmacokinetics
36	St. Justine's Hospital	Hospital	Interventional	Phase 1	Pharmacokinetics
37	Université Catholique de Louvain	University	Interventional	Phase 4	Pharmacokinetics
38	Assistance Publique - Hôpitaux de Paris	Hospital	Interventional	Not specified	Pharmacokinetics
39	Helsinki University   Foundation for Paediatric Research	University	Interventional	Phase 4	Safety/Efficacy
40	National Taiwan University Hospital	University	Interventional	Phase 4	Pharmacokinetics
41	Chulalongkorn University	University	Interventional	Not specified	Efficacy
42	University of Pittsburgh   National Institute of Allergy and Infectious Diseases	University	Interventional	Phase 3	Safety/Efficacy
43	Korea University	University	Interventional	Phase 4	Efficacy
44	Baylor College of Medicine   Forest Laboratories	University	Interventional	Phase 1-2	Safety/Efficacy
45	Royal College of Surgeons, Ireland   Health Research Board	University	Interventional	Phase 4	Efficacy
46	Ramon Gorter   ZonMw: The Netherlands Organisation for Scientific Research	University	Interventional	Phase 4	Efficacy
47	AstraZeneca   PRA Health Sciences	Industry	Interventional	Phase 2	Safety/Efficacy
48	Aga Khan University	University	Interventional	Not specified	Efficacy
49	Thammasat University	University	Interventional	Phase 4	Safety/Efficacy
50	Basilea Pharmaceutica	Industry	Interventional	Phase 1	Pharmacokinetics
51	Murdoch Childrens Research Institute   Royal Children's Hospital	University	Interventional	Not specified	Pharmacokinetics
52	AstraZeneca   PRA Health Sciences	Industry	Interventional	Phase 2	Safety/Efficacy
53	Durata Therapeutics Inc., an affiliate of Allergan	Industry	Interventional	Phase 3	Safety/Efficacy
54	Cempra Inc   National Institute of Allergy and Infectious Diseases	Industry	Interventional	Phase 3	Efficacy
55	Otonomy, Inc.	Industry	Interventional	Phase 3	Efficacy
56	Save the Children   University of North Carolina   UNC Children's Hospital	Health Organisation	Interventional	Phase 4	Efficacy
57	Save the Children   University of North Carolina   UNC Children's Hospital	Health Organisation	Interventional	Phase 4	Efficacy
58	Cempra Inc	Industry	Interventional	Phase 2-3	Safety/Efficacy
59	Cempra Inc	Industry	Interventional	Phase 3	Safety/Efficacy
60	Tanta University	University	Interventional	Phase 3	Efficacy
61	Murdoch Childrens Research Institute	University	Interventional	Not specified	Efficacy
62	Astellas Pharma Europe B.V.   Merck Sharp & Dohme	Industry	Interventional	Phase 3	Safety/Efficacy

	P	Q	R	S	T
63	Laboratorios Goulart S.A.	Industry	Interventional	Phase 3	Safety/Efficacy
64	University Hospital, Ghent   Universitair Ziekenhu	University	Interventional	Phase 4	Pharmacokinetics
65	Malaria Consortium   World Health Organization	Health Organisa	Interventional	Phase 4	Safety
66	PENTA Foundation   St George's, University of Lor	Health Organisa	Interventional	Phase 2	Safety/Efficacy
67	Sigvard Mì   Istad   Public Health Agency of Swede	University	Interventional	Phase 4	Safety/Efficacy
68	AstraZeneca   PRA Health Sciences	Industry	Interventional	Phase 2-3	Safety/Efficacy
69	The Medicines Company	Industry	Interventional	Phase 1	Pharmacokinetics
70	Theravance Biopharma Antibiotics, Inc.	Industry	Interventional	Phase 4	Pharmacokinetics
71	The Canberra Hospital	Hospital	Interventional	Phase 2	Pharmacokinetics
72	Chang Gung Memorial Hospital	Hospital	Interventional	Phase 4	Efficacy
73	Darier	Industry	Interventional	Phase 4	Safety/Efficacy
74	Theravance Biopharma Antibiotics, Inc.	Industry	Observational	Not applicable	Safety/Efficacy
75	Grupo de Apoio ao Adolescente e a Crianca com	Hospital	Observational	Not applicable	Pharmacokinetics
76	Infectopharm Arzneimittel GmbH   J&P Medical R	Industry	Observational	Not applicable	Efficacy
77	University of Maryland	University	Interventional	Phase 2	Safety/Efficacy

	U	V	W	X	Y	Z	AA	AB
1	<b>Primary outcome variable</b>	<b>PK data collected</b>	<b>First Receive</b>	<b>Start Date</b>	<b>Completion</b>	<b>Last Update</b>	<b>Last Verified</b>	<b>Results First Received</b>
2	PK	PK study design	July 2, 2015	Sep-15	Dec-18	September 1, 2016	Sep-16	No Study Results Posted
3	Efficacy	No PK data	September 2, 2016	Oct-16	null	October 12, 2016	Oct-16	No Study Results Posted
4	Efficacy	No PK data	September 8, 2016	Sep-16	null	September 1, 2016	Sep-16	No Study Results Posted
5	Efficacy	No PK data	May 8, 2012	May-12	Apr-18	June 27, 2016	Jun-16	No Study Results Posted
6	Efficacy	No PK data	March 2, 2016	Mar-16	May-18	March 24, 2016	Mar-16	No Study Results Posted
7	Efficacy	No PK data	September 1, 2016	Oct-16	Mar-19	October 13, 2016	Oct-16	No Study Results Posted
8	PK	PK study design	April 4, 2016	Apr-16	Sep-16	April 25, 2016	Apr-16	No Study Results Posted
9	Efficacy	No PK data	September 2, 2016	Oct-16	Dec-17	September 2, 2016	Sep-16	No Study Results Posted
10	Efficacy	No PK data	November 1, 2016	Dec-10	null	September 1, 2016	Sep-12	No Study Results Posted
11	Efficacy	No PK data	November 2, 2016	Mar-14	Jul-16	December 1, 2016	Nov-15	No Study Results Posted
12	PK	Primary PK data	January 26, 2012	Apr-12	Apr-18	December 1, 2016	Dec-15	No Study Results Posted
13	PK	PK study design	May 18, 2015	May-12	null	November 1, 2016	Nov-15	No Study Results Posted
14	Efficacy	No PK data	December 18, 2007	Dec-07	Sep-10	June 3, 2008	Aug-07	No Study Results Posted
15	Efficacy	No PK data	October 17, 2007	Nov-07	Dec-09	October 18, 2007	Oct-07	No Study Results Posted
16	PK	PK study design	August 17, 2011	Nov-11	Feb-17	February 4, 2016	Feb-16	No Study Results Posted
17	PK	PK study design	June 12, 2015	Nov-15	Dec-17	August 1, 2016	Aug-16	No Study Results Posted
18	Efficacy	No PK data	August 18, 2011	Aug-11	Dec-20	August 30, 2016	Aug-16	No Study Results Posted
19	PK	PK study design	September 2, 2014	Sep-14	Nov-16	October 31, 2016	Oct-16	No Study Results Posted
20	Efficacy	No PK data	March 23, 2009	Mar-09	Oct-12	June 21, 2011	Jun-11	No Study Results Posted
21	Safety	No PK data	August 23, 2016	Aug-16	Dec-16	September 1, 2016	Sep-16	No Study Results Posted
22	Efficacy	No PK data	January 3, 2011	Mar-11	Jun-15	May 25, 2015	May-15	No Study Results Posted
23	Safety	Secondary PK data	October 9, 2016	Mar-15	Jan-18	October 31, 2016	Oct-16	No Study Results Posted
24	Safety	Primary PK data	January 12, 2017	Jan-17	Dec-18	September 8, 2016	Sep-16	No Study Results Posted
25	Safety	No PK data	September 1, 2016	Jul-16	Sep-18	October 19, 2016	Oct-16	No Study Results Posted
26	Efficacy	No PK data	November 1, 2014	Jan-14	Jul-17	May 6, 2016	May-16	No Study Results Posted
27	Efficacy	No PK data	August 21, 2013	Aug-13	Aug-15	August 26, 2016	Aug-14	No Study Results Posted
28	PK	PK study design	May 11, 2016	Aug-16	Oct-22	May 17, 2016	May-16	No Study Results Posted
29	Safety	Primary PK data	February 17, 2016	Jul-16	Sep-19	October 6, 2016	Oct-16	No Study Results Posted
30	Efficacy	No PK data	May 5, 2016	Jun-16	Dec-20	October 7, 2016	Oct-16	No Study Results Posted
31	Safety	No PK data	November 1, 2013	Dec-13	Sep-17	August 1, 2016	Aug-16	No Study Results Posted



	U	V	W	X	Y	Z	AA	AB
32	Efficacy	No PK data	September 2	Nov-14	Dec-18	December 20	Dec-15	No Study Results Posted
33	PK	PK study design	February 18,	Apr-16	May-17	October 19, 2	Oct-16	No Study Results Posted
34	Efficacy	No PK data	May 8, 2006	Jan-04	Dec-13	February 6, 2	Feb-12	No Study Results Posted
35	PK	PK study design	April 1, 2016	May-16	Feb-18	October 21, 2	Oct-16	No Study Results Posted
36	PK	PK study design	June 2, 2015	Jan-16	Dec-17	April 18, 201	Apr-16	No Study Results Posted
37	PK	PK study design	October 1, 20	Oct-16	Oct-17	October 24, 2	Oct-16	No Study Results Posted
38	PK	PK study design	February 24,	Feb-16	Feb-17	March 8, 201	Mar-16	No Study Results Posted
39	Efficacy	No PK data	February 23,	Feb-12	Jul-17	February 19,	Feb-16	No Study Results Posted
40	PK	PK study design	August 23, 20	Jun-06	Dec-07	August 23, 20	Aug-06	No Study Results Posted
41	Efficacy	No PK data	January 30, 2	Dec-12	Dec-13	February 6, 2	Feb-13	No Study Results Posted
42	Efficacy	No PK data	September 8	Feb-16	Sep-20	October 3, 20	Oct-16	No Study Results Posted
43	Efficacy	No PK data	December 22	Apr-07	Apr-16	April 8, 2014	Apr-14	No Study Results Posted
44	Safety	Secondary PK data	December 31	Jan-15	Jan-20	June 24, 201	Jun-16	No Study Results Posted
45	Efficacy	No PK data	August 9, 20	Dec-16	Dec-19	September 3	Jul-16	No Study Results Posted
46	Efficacy	No PK data	July 24, 2016	Dec-16	Dec-20	July 26, 2016	Jul-16	No Study Results Posted
47	Safety	Secondary PK data	May 25, 2015	Jul-15	Oct-17	October 21, 2	Oct-16	No Study Results Posted
48	Efficacy	No PK data	November 4,	Nov-14	Jul-17	June 3, 2016	Jun-16	No Study Results Posted
49	Efficacy	No PK data	February 17,	Jan-12	Sep-12	March 13, 20	Mar-12	No Study Results Posted
50	PK	PK study design	August 5, 20	Aug-14	Jun-17	October 20, 2	Oct-16	No Study Results Posted
51	PK	PK study design	August 5, 20	Sep-14	Sep-17	March 17, 20	Mar-16	No Study Results Posted
52	Safety	Secondary PK data	June 16, 201	Sep-15	Oct-17	October 21, 2	Oct-16	No Study Results Posted
53	Efficacy	No PK data	June 8, 2016	Jun-16	Jul-18	June 23, 201	Jun-16	No Study Results Posted
54	Efficacy	No PK data	August 1, 20	Aug-14	Apr-17	September 2	Sep-16	No Study Results Posted
55	Efficacy	No PK data	June 13, 201	Jun-16	Nov-16	June 13, 201	Jun-16	No Study Results Posted
56	Efficacy	No PK data	May 1, 2016	Jun-16	Sep-18	June 10, 201	Jun-16	No Study Results Posted
57	Efficacy	No PK data	February 3, 2	Mar-16	null	June 10, 201	Jun-16	No Study Results Posted
58	Safety	No PK data	November 10	Mar-16	Jan-18	September 1	Sep-16	No Study Results Posted
59	Efficacy	No PK data	October 5, 20	Nov-15	Feb-17	October 5, 20	Oct-16	No Study Results Posted
60	Efficacy	No PK data	May 11, 2015	Jan-15	Dec-16	May 9, 2016	May-16	No Study Results Posted
61	Efficacy	No PK data	January 4, 20	Jan-15	Jan-17	March 16, 20	Mar-16	No Study Results Posted
62	Efficacy	No PK data	August 11, 20	Oct-14	Feb-17	June 17, 201	Jun-16	No Study Results Posted

	U	V	W	X	Y	Z	AA	AB
63	Efficacy	No PK data	December 14,	May-10	Oct-10	March 18, 20	Dec-09	No Study Results Posted
64	PK	PK study design	November 4,	Apr-15	Apr-16	November 4,	Nov-15	No Study Results Posted
65	Safety	No PK data	August 17, 20	Oct-16	Jul-17	October 3, 20	Oct-16	No Study Results Posted
66	Efficacy	Secondary PK data	April 7, 2016	Jul-16	Mar-18	May 31, 2016	May-16	No Study Results Posted
67	Efficacy	No PK data	March 4, 201	Sep-15	Oct-16	October 4, 20	Oct-16	No Study Results Posted
68	Safety	Secondary PK data	February 23,	Aug-15	Oct-17	October 14, 2	Oct-16	No Study Results Posted
69	PK	PK study design	May 7, 2014	May-14	Dec-16	November 4,	Nov-15	No Study Results Posted
70	PK	PK study design	December 11	Dec-14	Aug-16	June 24, 2010	Jun-16	No Study Results Posted
71	PK	PK study design	August 31, 20	Aug-11	Jul-12	September 1	Aug-11	No Study Results Posted
72	Efficacy	No PK data	November 25	Aug-10	Jul-12	January 14, 2	Nov-10	No Study Results Posted
73	Efficacy	No PK data	September 3	Jun-09	Apr-10	September 3	Sep-09	No Study Results Posted
74	Efficacy	No PK data	November 5,	Nov-14	Sep-18	June 29, 2010	Jun-16	No Study Results Posted
75	PK	Primary PK data	February 24,	Jan-11	null	March 21, 20	Mar-12	No Study Results Posted
76	Efficacy	No PK data	July 29, 2010	Aug-10	null	February 5, 2	Feb-16	No Study Results Posted
77	Efficacy	Secondary PK data	January 22, 2	Jul-13	Dec-21	May 28, 2015	May-15	No Study Results Posted

	AC	AD	AE	AF	AG
1	<b>Primary Com</b>	<b>URL</b>			
2	Jul-18	<a href="https://ClinicalTrials.gov/show/NCT02539407">https://ClinicalTrials.gov/show/NCT02539407</a>			
3	Dec-18	<a href="https://ClinicalTrials.gov/show/NCT02935374">https://ClinicalTrials.gov/show/NCT02935374</a>			
4	Sep-18	<a href="https://ClinicalTrials.gov/show/NCT02899143">https://ClinicalTrials.gov/show/NCT02899143</a>			
5	Apr-18	<a href="https://ClinicalTrials.gov/show/NCT01595529">https://ClinicalTrials.gov/show/NCT01595529</a>			
6	Feb-18	<a href="https://ClinicalTrials.gov/show/NCT02380352">https://ClinicalTrials.gov/show/NCT02380352</a>			
7	Jan-19	<a href="https://ClinicalTrials.gov/show/NCT02891915">https://ClinicalTrials.gov/show/NCT02891915</a>			
8	Sep-16	<a href="https://ClinicalTrials.gov/show/NCT02746276">https://ClinicalTrials.gov/show/NCT02746276</a>			
9	Aug-17	<a href="https://ClinicalTrials.gov/show/NCT02917551">https://ClinicalTrials.gov/show/NCT02917551</a>			
10	Jun-13	<a href="https://ClinicalTrials.gov/show/NCT01243437">https://ClinicalTrials.gov/show/NCT01243437</a>			
11	Mar-16	<a href="https://ClinicalTrials.gov/show/NCT02635191">https://ClinicalTrials.gov/show/NCT02635191</a>			
12	Dec-16	<a href="https://ClinicalTrials.gov/show/NCT01522105">https://ClinicalTrials.gov/show/NCT01522105</a>			
13	Dec-17	<a href="https://ClinicalTrials.gov/show/NCT02456974">https://ClinicalTrials.gov/show/NCT02456974</a>			
14	Sep-10	<a href="https://ClinicalTrials.gov/show/NCT00579956">https://ClinicalTrials.gov/show/NCT00579956</a>			
15	null	<a href="https://ClinicalTrials.gov/show/NCT00545961">https://ClinicalTrials.gov/show/NCT00545961</a>			
16	Feb-17	<a href="https://ClinicalTrials.gov/show/NCT01431326">https://ClinicalTrials.gov/show/NCT01431326</a>			
17	Nov-17	<a href="https://ClinicalTrials.gov/show/NCT02475876">https://ClinicalTrials.gov/show/NCT02475876</a>			
18	Dec-20	<a href="https://ClinicalTrials.gov/show/NCT01420341">https://ClinicalTrials.gov/show/NCT01420341</a>			
19	Nov-16	<a href="https://ClinicalTrials.gov/show/NCT02266706">https://ClinicalTrials.gov/show/NCT02266706</a>			
20	Sep-12	<a href="https://ClinicalTrials.gov/show/NCT00867789">https://ClinicalTrials.gov/show/NCT00867789</a>			
21	Dec-16	<a href="https://ClinicalTrials.gov/show/NCT02879981">https://ClinicalTrials.gov/show/NCT02879981</a>			
22	Jun-15	<a href="https://ClinicalTrials.gov/show/NCT01269541">https://ClinicalTrials.gov/show/NCT01269541</a>			
23	Jan-18	<a href="https://ClinicalTrials.gov/show/NCT02276482">https://ClinicalTrials.gov/show/NCT02276482</a>			
24	Dec-18	<a href="https://ClinicalTrials.gov/show/NCT02663596">https://ClinicalTrials.gov/show/NCT02663596</a>			
25	Sep-17	<a href="https://ClinicalTrials.gov/show/NCT02555059">https://ClinicalTrials.gov/show/NCT02555059</a>			
26	Apr-17	<a href="https://ClinicalTrials.gov/show/NCT02297815">https://ClinicalTrials.gov/show/NCT02297815</a>			
27	Dec-14	<a href="https://ClinicalTrials.gov/show/NCT02224040">https://ClinicalTrials.gov/show/NCT02224040</a>			
28	Aug-22	<a href="https://ClinicalTrials.gov/show/NCT02775968">https://ClinicalTrials.gov/show/NCT02775968</a>			
29	Aug-19	<a href="https://ClinicalTrials.gov/show/NCT02687906">https://ClinicalTrials.gov/show/NCT02687906</a>			
30	Dec-19	<a href="https://ClinicalTrials.gov/show/NCT02783859">https://ClinicalTrials.gov/show/NCT02783859</a>			
31	Apr-17	<a href="https://ClinicalTrials.gov/show/NCT01994993">https://ClinicalTrials.gov/show/NCT01994993</a>			

	AC	AD	AE	AF	AG
32	Dec-17	<a href="https://ClinicalTrials.gov/show/NCT02258763">https://ClinicalTrials.gov/show/NCT02258763</a>			
33	May-17	<a href="https://ClinicalTrials.gov/show/NCT02688790">https://ClinicalTrials.gov/show/NCT02688790</a>			
34	Dec-12	<a href="https://ClinicalTrials.gov/show/NCT00323219">https://ClinicalTrials.gov/show/NCT00323219</a>			
35	Feb-18	<a href="https://ClinicalTrials.gov/show/NCT02750761">https://ClinicalTrials.gov/show/NCT02750761</a>			
36	Dec-17	<a href="https://ClinicalTrials.gov/show/NCT02466438">https://ClinicalTrials.gov/show/NCT02466438</a>			
37	Sep-17	<a href="https://ClinicalTrials.gov/show/NCT02260102">https://ClinicalTrials.gov/show/NCT02260102</a>			
38	Jun-16	<a href="https://ClinicalTrials.gov/show/NCT02694458">https://ClinicalTrials.gov/show/NCT02694458</a>			
39	Feb-17	<a href="https://ClinicalTrials.gov/show/NCT01540838">https://ClinicalTrials.gov/show/NCT01540838</a>			
40	null	<a href="https://ClinicalTrials.gov/show/NCT00368498">https://ClinicalTrials.gov/show/NCT00368498</a>			
41	Dec-13	<a href="https://ClinicalTrials.gov/show/NCT01785641">https://ClinicalTrials.gov/show/NCT01785641</a>			
42	Sep-20	<a href="https://ClinicalTrials.gov/show/NCT02554383">https://ClinicalTrials.gov/show/NCT02554383</a>			
43	Mar-16	<a href="https://ClinicalTrials.gov/show/NCT01265173">https://ClinicalTrials.gov/show/NCT01265173</a>			
44	Jan-17	<a href="https://ClinicalTrials.gov/show/NCT02335905">https://ClinicalTrials.gov/show/NCT02335905</a>			
45	Dec-19	<a href="https://ClinicalTrials.gov/show/NCT02922686">https://ClinicalTrials.gov/show/NCT02922686</a>			
46	Dec-20	<a href="https://ClinicalTrials.gov/show/NCT02848820">https://ClinicalTrials.gov/show/NCT02848820</a>			
47	Oct-17	<a href="https://ClinicalTrials.gov/show/NCT02475733">https://ClinicalTrials.gov/show/NCT02475733</a>			
48	May-17	<a href="https://ClinicalTrials.gov/show/NCT02372461">https://ClinicalTrials.gov/show/NCT02372461</a>			
49	Aug-12	<a href="https://ClinicalTrials.gov/show/NCT01553006">https://ClinicalTrials.gov/show/NCT01553006</a>			
50	Mar-17	<a href="https://ClinicalTrials.gov/show/NCT02527681">https://ClinicalTrials.gov/show/NCT02527681</a>			
51	Sep-17	<a href="https://ClinicalTrials.gov/show/NCT02210169">https://ClinicalTrials.gov/show/NCT02210169</a>			
52	Oct-17	<a href="https://ClinicalTrials.gov/show/NCT02497781">https://ClinicalTrials.gov/show/NCT02497781</a>			
53	Apr-18	<a href="https://ClinicalTrials.gov/show/NCT02814916">https://ClinicalTrials.gov/show/NCT02814916</a>			
54	Apr-17	<a href="https://ClinicalTrials.gov/show/NCT02210325">https://ClinicalTrials.gov/show/NCT02210325</a>			
55	Nov-16	<a href="https://ClinicalTrials.gov/show/NCT02801370">https://ClinicalTrials.gov/show/NCT02801370</a>			
56	Aug-18	<a href="https://ClinicalTrials.gov/show/NCT02760420">https://ClinicalTrials.gov/show/NCT02760420</a>			
57	Aug-18	<a href="https://ClinicalTrials.gov/show/NCT02678195">https://ClinicalTrials.gov/show/NCT02678195</a>			
58	Dec-17	<a href="https://ClinicalTrials.gov/show/NCT02605122">https://ClinicalTrials.gov/show/NCT02605122</a>			
59	Feb-17	<a href="https://ClinicalTrials.gov/show/NCT02570490">https://ClinicalTrials.gov/show/NCT02570490</a>			
60	Dec-16	<a href="https://ClinicalTrials.gov/show/NCT02443285">https://ClinicalTrials.gov/show/NCT02443285</a>			
61	Jan-17	<a href="https://ClinicalTrials.gov/show/NCT02334124">https://ClinicalTrials.gov/show/NCT02334124</a>			
62	Feb-17	<a href="https://ClinicalTrials.gov/show/NCT02218372">https://ClinicalTrials.gov/show/NCT02218372</a>			

	AC	AD	AE	AF	AG
63	Jul-10	<a href="https://ClinicalTrials.gov/show/NCT01032499">https://ClinicalTrials.gov/show/NCT01032499</a>			
64	Feb-16	<a href="https://ClinicalTrials.gov/show/NCT02598362">https://ClinicalTrials.gov/show/NCT02598362</a>			
65	Mar-17	<a href="https://ClinicalTrials.gov/show/NCT02878031">https://ClinicalTrials.gov/show/NCT02878031</a>			
66	Dec-17	<a href="https://ClinicalTrials.gov/show/NCT02790996">https://ClinicalTrials.gov/show/NCT02790996</a>			
67	Oct-16	<a href="https://ClinicalTrials.gov/show/NCT02712307">https://ClinicalTrials.gov/show/NCT02712307</a>			
68	Oct-17	<a href="https://ClinicalTrials.gov/show/NCT02424734">https://ClinicalTrials.gov/show/NCT02424734</a>			
69	Dec-16	<a href="https://ClinicalTrials.gov/show/NCT02134301">https://ClinicalTrials.gov/show/NCT02134301</a>			
70	Aug-16	<a href="https://ClinicalTrials.gov/show/NCT02013141">https://ClinicalTrials.gov/show/NCT02013141</a>			
71	Jul-12	<a href="https://ClinicalTrials.gov/show/NCT01427842">https://ClinicalTrials.gov/show/NCT01427842</a>			
72	Jun-11	<a href="https://ClinicalTrials.gov/show/NCT01278017">https://ClinicalTrials.gov/show/NCT01278017</a>			
73	Feb-10	<a href="https://ClinicalTrials.gov/show/NCT00988026">https://ClinicalTrials.gov/show/NCT00988026</a>			
74	Jun-18	<a href="https://ClinicalTrials.gov/show/NCT02288234">https://ClinicalTrials.gov/show/NCT02288234</a>			
75	null	<a href="https://ClinicalTrials.gov/show/NCT01304459">https://ClinicalTrials.gov/show/NCT01304459</a>			
76	Dec-16	<a href="https://ClinicalTrials.gov/show/NCT01173575">https://ClinicalTrials.gov/show/NCT01173575</a>			
77	Dec-19	<a href="https://clinicaltrials.gov/ct2/show/NCT01778634">https://clinicaltrials.gov/ct2/show/NCT01778634</a>			